现代仪器与医疗
現代儀器與醫療
현대의기여의료
Modern Instrument and Medical Treatment
2014年
2期
45-47,21
,共4页
间歇治疗%前列腺癌%血管内皮生长因子%miR-34a
間歇治療%前列腺癌%血管內皮生長因子%miR-34a
간헐치료%전렬선암%혈관내피생장인자%miR-34a
intermittent therapy%prostate cancer%vascular endothelial growth factor%miR-34a
目的：探讨戈舍瑞林联合比卡鲁胺间歇治疗对前列腺癌患者血管内皮生长因子（VEGF）和miR-34a的影响。方法：选择2007年12月-2012年6月收治的晚期前列腺癌患者83例为研究对象，采用戈舍瑞林联合比卡鲁胺的间歇内分泌治疗，治疗9个月后评价疗效。测定治疗前后患者血清的VEGF和miR-34a。结果：患者的前列腺体积和血清前列腺特异性抗原（PSA）在治疗后均有明显减少，与治疗前比较差异显著（P<0.01）；前列腺体积变化率平均为36.4%，PSA抑制率为63.6%。治疗后患者血清VEGF均明显降低（P<0.01），治疗后血清miR-34a明显升高（P<0.01）。结论：戈舍瑞林联合比卡鲁胺间歇内分泌治疗可以明显减少前列腺癌血清VEGF，提高miR-34a的表达。
目的：探討戈捨瑞林聯閤比卡魯胺間歇治療對前列腺癌患者血管內皮生長因子（VEGF）和miR-34a的影響。方法：選擇2007年12月-2012年6月收治的晚期前列腺癌患者83例為研究對象，採用戈捨瑞林聯閤比卡魯胺的間歇內分泌治療，治療9箇月後評價療效。測定治療前後患者血清的VEGF和miR-34a。結果：患者的前列腺體積和血清前列腺特異性抗原（PSA）在治療後均有明顯減少，與治療前比較差異顯著（P<0.01）；前列腺體積變化率平均為36.4%，PSA抑製率為63.6%。治療後患者血清VEGF均明顯降低（P<0.01），治療後血清miR-34a明顯升高（P<0.01）。結論：戈捨瑞林聯閤比卡魯胺間歇內分泌治療可以明顯減少前列腺癌血清VEGF，提高miR-34a的錶達。
목적：탐토과사서림연합비잡로알간헐치료대전렬선암환자혈관내피생장인자（VEGF）화miR-34a적영향。방법：선택2007년12월-2012년6월수치적만기전렬선암환자83례위연구대상，채용과사서림연합비잡로알적간헐내분비치료，치료9개월후평개료효。측정치료전후환자혈청적VEGF화miR-34a。결과：환자적전렬선체적화혈청전렬선특이성항원（PSA）재치료후균유명현감소，여치료전비교차이현저（P<0.01）；전렬선체적변화솔평균위36.4%，PSA억제솔위63.6%。치료후환자혈청VEGF균명현강저（P<0.01），치료후혈청miR-34a명현승고（P<0.01）。결론：과사서림연합비잡로알간헐내분비치료가이명현감소전렬선암혈청VEGF，제고miR-34a적표체。
Objective:To study intermittent therapy of goserelin plus bicalutamide on serum vascular endothelial growth factor(VEGF) and miR-34a in patients with prostate cancer. Methods:From December 2007-June 2012, 83 patients with advanced prostate cancer were enrolled as an object of study. They were treated through goserelin plus bicalutamide for nine months. Serum VEGF and miR-34a before and after were detected. Results:Patients of prostate volume and serum prostate-specific antigen (PSA) were significantly reduced after treatment, compared with before treatment signiifcantly different (P <0.01). Prostate volume change rate averaged 36.4%, PSA inhibition rate was 63.6%. After treatment, serum VEGF was significantly lower (P <0.01), serum miR-34a was signiifcantly higher (P<0.01). Conclusions:Intermittent therapy of goserelin plus bicalutamide can signiifcantly decrease serum VEGF and miR-34a in patients with prostate cancer.
